Regulatory and Safety Aspects of Cell and Gene Therapy
Cell therapy products require a variety of safety considerations. Stem cell and gene products are heterogeneous substances. There are several areas that particularly need to be addressed as it is quite different from that of pharmaceuticals. These range from creating batch consistency, product stability to product safety, strength and efficacy through pre-clinical, clinical studies and marketing authorization. This review summarizes the existing regulations/guidelines in US, EU, India, and the associated challenges in developing SCBP with emphasis on clinical aspect.
- Guidelines of cell therapy
- safety precautions
Related Conference of Regulatory and Safety Aspects of Cell and Gene Therapy
March 09-10, 2026
21th World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
Singapore City, Singapore
June 18-19, 2026
16th International Conference on Human Genetics and Genetic Diseases
Singapore City, Singapore
June 18-19, 2026
19th International Conference on Genomics & Pharmacogenomics
Singapore City, Singapore
Regulatory and Safety Aspects of Cell and Gene Therapy Conference Speakers
Recommended Sessions
- Advanced Gene Therapeutics
- Bioengineering Therapeutics
- Cell and Gene Therapy for Rare & Common Diseases
- Cell Culture and Bioprocessing
- Cell Science and stem cell research
- Cell Therapy
- Cell Therapy for Cardiovascular and Neurological Disorders
- Clinical Trials on Cell & Gene Therapy
- Ethical Issues in Cell and Gene Therapy
- Gene Therapy
- Genetics & Genomic Medicine
- Genome Editing
- Markets & Future Prospects for Cell & Gene Therapy
- Molecular Basis of Epigenetics
- Nano Therapy
- Regulatory and Safety Aspects of Cell and Gene Therapy
- Stem Cell Research
- Stem Cell Therapies
- Tissue Engineering & Regenerative Medicine
- Viral Gene Therapy
Related Journals
Are you interested in
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (France)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (France)
- Cancer Stem Cells and Oncology - Stemgen 2026 (France)
- Cardiovascular Regeneration - Stemgen 2026 (France)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (France)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (France)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (France)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (France)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (France)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (France)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (France)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (France)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (France)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (France)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (France)